Glioma Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma (2011)

    Gliobastoma multiforme is highly resistant to current cancer treatments. However, the combined administration of D9 tetrahydrocannabinol and temozolomide exerts a strong antitumor action on glioma xenografts, suggesting that it could be exploited therapeutically for the treatment of gliobastoma multiforme. View study

  • Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines (2004)

    In this study, the in vitro antiproliferative capacity of cannabidiol (CBD), a non-psychoactive cannabinoid compound, in U87 and U373 human glioma cell lines is evaluated. According to the results obtained, it could be concluded that non-psychoactive CBD was able to produce significant antitumor activity both in vitro and in vivo, suggesting a possible application of CBD as an antineoplastic agent View study

  • Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism (2005)

    The results of this investigation reinforced the evidence of the antitumor properties of cannabidiol (CBD) and also demonstrated its ability to limit tumor invasion. View study

  • Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect (2013)

    According to the results obtained, it could be concluded that the non-psychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, which suggests a possible application of CBD as an antineoplastic agent. View study

  • Cannabinoids Inhibit Glioma Cell Invasion by Down-regulating Matrix Metalloproteinase-2 Expression (2008)

    In this research, the effect of cannabinoids on the expression of matrix metalloproteinase (MMP) and its effect on the invasion of tumor cells was evaluated. The local administration of # 9 -tetrahydrocannabinol (THC), the main active ingredient of cannabis, the expression of MMP-2 regulated downward in gliomas generated in mice, as determined by Western blot, immunofluorescence and quantitative PCR analysis in real time. View study

  • Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas (2004)

    This research was based on the study on whether cannabinoids inhibit the vascular endothelial growth factor (VEGF) pathway in gliomas. The findings found provide a new pharmacological objective for cannabinoid-based therapies. View study

  • Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor (2016)

    This investigation shows that local administration of the selective CB2 agonist JWH-133 at 50 mg / day to Rag-22/2 mice induced a considerable regression of malignant tumors generated by the inoculation of C6 glioma cells. It could be observed in the experiments carried out with C6 glioma cells in culture, evidenced the internalization of the CB2 receptor but not the CB1 receptor after the challenge JWH-133 and showed that the selective activation of the CB2 receptor indicated the apoptosis through the synthesis Improved de novo ceramide View study

  • Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma ()

    The median historical survival of patients with glioblastoma multiforme (GBM) with the best radiological, surgical and antitumor pharmacological treatment available is less than one year, depending on age and other prognostic factors. This research aimed to test in vitro and in vitro the safety and efficacy of a new chemotherapeutic agent KM-233 for the treatment of glioma. It could be concluded that these studies provided both in vitro and in vitro evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vitro studies View study

  • Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas ()

    This systematic review of the literature on clinical and experimental trials aimed to evaluate the antitumor effects of cannabinoids on gliomas. View study